StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note issued to investors on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 5.0 %
Evoke Pharma stock opened at $0.46 on Friday. The firm has a market capitalization of $3.88 million, a PE ratio of -0.20 and a beta of 0.22. Evoke Pharma has a 52 week low of $0.42 and a 52 week high of $2.40. The firm’s 50-day simple moving average is $0.59 and its 200 day simple moving average is $0.89.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%. The business had revenue of $1.68 million for the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- How Can Investors Benefit From After-Hours Trading
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- How to Evaluate a Stock Before Buying
- MarketBeat Week in Review – 4/22 – 4/26
- Ride Out The Recession With These Dividend Kings
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
